We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-5.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.54B
AUM Growth
-$303M
Cap. Flow
-$71.8M
Cap. Flow %
-2.82%
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
27
Reduced
36
Closed
3

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14M
2
ISRG icon
Intuitive Surgical
ISRG
+$11.4M
3
BSX icon
Boston Scientific
BSX
+$9.19M
4
AZN icon
AstraZeneca
AZN
+$8.8M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$8.52M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.5M
2
MCK icon
McKesson
MCK
+$14.5M
3
MDT icon
Medtronic
MDT
+$11M
4
LLY icon
Eli Lilly
LLY
+$10.6M
5
ILMN icon
Illumina
ILMN
+$7.92M

Sector Composition

Rank Sector Weight
1 Healthcare 95.42%
2 Real Estate 3.13%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGEN icon
151
Qiagen
QGEN
$8.54B
$496K 0.02%
9,902
-91,811
-90% -$4.48M
HARP
152
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$496K 0.02%
25,991
– –
EWTX icon
153
Edgewise Therapeutics
EWTX
$4.13B
$482K 0.02%
60,550
– –
ITOS
154
DELISTED
iTeos Therapeutics
ITOS
$436K 0.02%
21,181
-21,181
-50% -$503K
RPTX
155
DELISTED
Repare Therapeutics
RPTX
$408K 0.02%
29,150
– –
UHS icon
156
Universal Health Services
UHS
$10.2B
$403K 0.02%
4,000
– –
MOR
157
DELISTED
MorphoSys AG American Depositary Shares
MOR
$396K 0.02%
81,867
– –
EMBC icon
158
Embecta
EMBC
$216M
$374K 0.01%
+14,786
New +$426K
DTIL icon
159
Precision BioSciences
DTIL
$180M
$359K 0.01%
7,484
– –
NKTX icon
160
Nkarta
NKTX
$150M
$357K 0.01%
28,988
– –
BCYC
161
Bicycle Therapeutics
BCYC
$269M
$337K 0.01%
20,065
+9,979
+99% +$210K
CYH icon
162
Community Health Systems
CYH
$393M
$331K 0.01%
88,335
– –
BDTX icon
163
Black Diamond Therapeutics
BDTX
$96.8M
$325K 0.01%
131,990
– –
ARDX icon
164
Ardelyx
ARDX
$1.22B
$318K 0.01%
539,408
– –
FULC icon
165
Fulcrum Therapeutics
FULC
$239M
$287K 0.01%
58,537
-18,756
-24% -$183K
ONEM
166
DELISTED
1Life Healthcare
ONEM
$245K 0.01%
31,266
– –
ENDP
167
DELISTED
Endo International plc
ENDP
$230K 0.01%
494,607
– –
ZIMV
168
DELISTED
ZimVie
ZIMV
$227K 0.01%
14,202
– –
PRAX icon
169
Praxis Precision Medicines
PRAX
$8.58B
$184K 0.01%
5,000
– –
FUSN
170
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$108K ﹤0.01%
43,394
– –
SPPI
171
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$89K ﹤0.01%
114,670
– –
ORKA
172
Oruka Therapeutics
ORKA
$5.82B
$81K ﹤0.01%
2,705
– –
YARW
173
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$53K ﹤0.01%
150
– –
CRBP icon
174
Corbus Pharmaceuticals
CRBP
$166M
$39K ﹤0.01%
5,144
– –
ALR
175
DELISTED
AlerisLife Inc
ALR
$29K ﹤0.01%
24,237
– –
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Tekla Capital Management held 180 positions worth $2.54B, down 11% from $2.85B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Trading was light in Q2 2022: portfolio turnover was 4.4%. Tekla Capital Management opened 5 new positions and exited 3, leaving the 180-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q2 2022 buy was Lantheus: 127,092 shares worth $8.39M.
  • Tekla Capital Management added most to Vertex Pharmaceuticals in Q2 2022, an estimated $14M increase.
  • Tekla Capital Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $19.5M.
  • Tekla Capital Management fully exited Revvity in Q2 2022, selling an estimated $5.83M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.54B portfolio in Q2 2022.
  • Tekla Capital Management opened 5 new positions and closed 3 in Q2 2022.
  • Tekla Capital Management's portfolio value fell 11% quarter-over-quarter to $2.54B.

Based on Tekla Capital Management's 13F filing for Q2 2022, filed 29 Jul 2022.